AGCO to Present at the 2021 Jefferies Virtual Industrials Conference

DULUTH, Ga.--(BUSINESS WIRE)-- AGCO, Your Agriculture Company (NYSE: AGCO), a worldwide manufacturer and distributor of agricultural equipment and infrastructure, announced today that it will participate in the 2021 Jefferies Virtual Industrials Conference on August 3, 2021. The conference will include a presentation by Andy Beck, AGCO's Senior Vice President and Chief Financial Officer at 11:30 a.m. E.D.T. Investors may listen to a live webcast of the presentation by accessing the webcast button in the "Investors" section of the Company’s website at http://www.agcocorp.com/company/investors.aspx. The webcast will also be archived immediately afterward.

About AGCO

AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Challenger®, Fendt®, GSI®, Massey Ferguson® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $9.1 billion in 2020. For more information, visit www.AGCOcorp.com. For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.

Please visit our website at www.agcocorp.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210730005091/en/

Greg Peterson
Vice President, Investor Relations
(770) 232-8229
[email protected]

Source: AGCO

You May Also Be Interested In

• Best’s Market Segment Report: Asia-Pacific Reinsurers Show Resilience Amid Evolving Market Landscapes
• Hyperliquid (HYPE) News: HYPE Hits $82 All-Time High After White House Boost as AlphaPepe Eyes Its Own Launch Breakout
• Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion